DJBIC Korea recognizes Hanmi’s climate governance and access to medicines.
Company highlights carbon neutrality roadmap and “no-patent” policy for low-income countries.
Hanmi Pharm’s ESG management is built into its everyday business, supporting its repeat inclusion in the Dow Jones Best-in-Class Korea Index.
Hanmi Pharm announced on the 13th that it has been included in the Dow Jones Best-in-Class (DJBIC) Korea Index for a second consecutive year. This sustainability benchmark is based on S&P Global’s Corporate Sustainability Assessment. The index selects long-term ESG leaders from the 200 largest Korean companies by free-float market capitalization, limiting constituents to the top 30 percent by sustainability performance. A company official said the continued inclusion reflects Hanmi’s efforts to integrate ESG into its core business strategy.
DJBIC, which replaced the former Dow Jones Sustainability Index (DJSI) in February last year, evaluates companies on environmental, social, and governance criteria alongside financial performance. It draws on CSA results to support responsible investment decisions by global asset owners and managers. The assessment covers governance, ethics and compliance, risk management, climate strategy, and human capital, as well as industry-specific issues.
Hanmi Pharm received strong scores in several areas, including carbon neutrality and environmental management governance, a preventive safety and health system, and measures to improve access to medicines. The company operates an hEHS Committee led by the CEO and representatives from five plants to oversee environment, health, and safety across the group. Established in 2019, the committee sets mid- to long-term decarbonization plans and monitors progress to minimize environmental impact.
The company has built a “self-regulated prevention system” requiring each site to identify and address potential safety risks in advance. Findings from this internal monitoring feed into semiannual safety inspections by third-party and headquarters teams, with immediate remediation when issues are detected. Hanmi says this framework supports a shift from reactive to preventive safety management in its operations.
To enhance access to medicines in least developed and low-income countries, Hanmi maintains a “no-patent” policy for some of its products and pipeline assets in selected markets. The approach allows local manufacturers to produce and supply generic versions without restriction, which the company says helps expand treatment options and improve public health. CEO Hwang Sang-yeon said the repeat inclusion in DJBIC Korea shows that its priorities in carbon neutrality and access to medicines are being recognized, and added that Hanmi will continue to strengthen ESG management in line with global standards.
By Min Byung-kwun, KDFN
kdf＠kdfnews.com
댓글
0